Decitabine application combined with allogeneic hematopoietic stem cell transplantation for treatment of acute leukemia progressed from myelodysplastic syndrome

doi:10.3969/j.issn.2095-4344.2012.49.024

Abstract

Abstract:

BACKGROUND: Acute leukemia progressed from myelodysplastic syndrome is a refractory disease with poor clinical therapeutic effect, low remission rate and short survival period. Therefore, it is extremely important to explore a new and effective treatment method.
OBJECTIVE: To investigate the clinical therapeutic effects and complications of decitabine application combined with allogeneic hematopoietic stem cell transplantation in treatment of acute leukemia progressed from myelodysplastic syndrome.
METHODS: One patient with acute leukemia progressed from myelodysplastic syndrome received two courses of decitabine application combined with allogeneic hematopoietic stem cell transplantation. Clinical curative effects, the side effects of decitabine and the complications of allogeneic hematopoietic stem cell transplantation were investigated.
RESULTS AND CONCLUSION: The patient achieved complete remission after two courses of decitabine application combined with allogeneic hematopoietic stem cell transplantation with infection and myelosuppresison. The patient lived without disease for 213 days although acute graft-versus-host disease and pulmonary infection occurred after decitabine application combined with allogeneic hematopoietic stem cell transplantation. These findings suggest that decitabine application combined with allogeneic hematopoietic stem cell transplantation is an effective method to treat acute leukemia progressed from myelodysplastic syndrome, and the side effects and complications can be well controlled.

CLC Number:

R394.2

Li Xu-dong, He Yi, Hu Yuan, Xiao Ruo-zhi, Fang Zhi-gang, Zheng Yong-jiang, Liu Jia-jun, Lin Dong-jun. Decitabine application combined with allogeneic hematopoietic stem cell transplantation for treatment of acute leukemia progressed from myelodysplastic syndrome[J]. Chinese Journal of Tissue Engineering Research, 2012, 16(49): 9253-9256.

Figures/Tables 1

References

[1] Meletis J, Viniou N, Terpos E.Novel agents for the management of myelodysplastic syndromes.Med Sci Monit. 2006;12(9):RA194-206.

[2] Srinivasan S, Schiffer CA.Current treatment options and strategies for myelodysplastic syndromes.Expert Opin Pharmacother. 2008;9(10):1667-1678.

[3] Daskalakis M, Nguyen TT, Nguyen C,et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.Blood. 2002;100(8):2957-2964.

[4] Dhodapkar M, Grill J, Lust JA.Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes.Leuk Res. 1995;19(10):719-726.

[5] Kantarjian H, Issa JP, Rosenfeld CS,et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.Cancer. 2006;106 (8):1794-1803.

[6] Wijermans PW, Lübbert M, Verhoef G,et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.Ann Hematol. 2005;84 Suppl 1: 9-17.

[7] Nimer SD.Myelodysplastic syndromes.Blood. 2008;111(10): 4841-4851.

[8] Epling-Burnette PK, List AF.Advancements in the molecular pathogenesis of myelodysplastic syndrome.Curr Opin Hematol. 2009;16(2):70-76.

[9] Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Cooperative Study Group.Cancer Genet Cytogenet. 1988;32(1):1-10.

[10] Morel P, Hebbar M, Lai JL,et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.Leukemia. 1993;7(9): 1315-1323.

[11] Solé F, Espinet B, Sanz GF,et al.Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica.Br J Haematol. 2000;108(2):346-356.

[12] Herman JG, Baylin SB.Gene silencing in cancer in association with promoter hypermethylation.N Engl J Med. 2003;349(21):2042-2054.

[13] El-Osta A. The rise and fall of genomic methylation in cancer. Leukemia. 2004;18(2):233-237.

[14] Tien HF, Tang JH, Tsay W,et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation.Br J Haematol. 2001; 112(1):148-154.

[15] Lakshmikuttyamma A, Scott SA, DeCoteau JF,et al. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.Oncogene. 2010; 29(4):576-588.

[16] Fang MS,Long SP,Li L,et al.Jinggangshan Daxue Xuebao: Ziran Kexueban. 2010;31(3):102-103.方木水,龙生平,黎龙,等.地西他滨治疗骨髓增生异常综合征转急性白血病1例并文献复习[J].井冈山大学学报:自然科学版,2010, 31(3):102-103.

[17] Cutler C.Patient selection for transplantation in the myelodysplastic syndromes.Hematol Oncol Clin North Am. 2010;24(2):469-476.

[18] Greenberg PL, Attar E, Bennett JM,et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.J Natl Compr Canc Netw. 2011;9(1):30-56.

[19] Zhang Q,Bai H,Wang CB,et al.Linchuang Xueyexue Zazhi. 2008;21(3):165-166.张茜,白海,王存邦,等.HLA相合同胞异基因造血干细胞移植治疗儿童MDS转变的AML 1例[J].临床血液学杂志,2008,21(3): 165-166.